- Home
- ALX vs ANAB Comparison
ALX vs ANAB Comparison
Compare ALX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- ANAB
- Stock Information
- Founded
- ALX 1928
- ANAB 2005
- Country
- ALX United States
- ANAB United States
- Employees
- ALX N/A
- ANAB N/A
- Industry
- ALX Real Estate Investment Trusts
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- ANAB Health Care
- Exchange
- ALX Nasdaq
- ANAB Nasdaq
- Market Cap
- ALX 1.2B
- ANAB 1.0B
- IPO Year
- ALX N/A
- ANAB 2017
- Fundamental
- Price
- ALX $207.55
- ANAB $41.30
- Analyst Decision
- ALX
- ANAB Buy
- Analyst Count
- ALX 0
- ANAB 12
- Target Price
- ALX N/A
- ANAB $63.40
- AVG Volume (30 Days)
- ALX 60.7K
- ANAB 708.8K
- Earning Date
- ALX 11-03-2025
- ANAB 11-04-2025
- Dividend Yield
- ALX 8.67%
- ANAB N/A
- EPS Growth
- ALX N/A
- ANAB N/A
- EPS
- ALX 7.14
- ANAB N/A
- Revenue
- ALX $215,838,000.00
- ANAB $169,467,000.00
- Revenue This Year
- ALX N/A
- ANAB $37.52
- Revenue Next Year
- ALX N/A
- ANAB N/A
- P/E Ratio
- ALX $29.07
- ANAB N/A
- Revenue Growth
- ALX N/A
- ANAB 196.42
- 52 Week Low
- ALX $184.76
- ANAB $12.21
- 52 Week High
- ALX $260.84
- ANAB $40.96
- Technical
- Relative Strength Index (RSI)
- ALX 39.00
- ANAB 71.97
- Support Level
- ALX $201.28
- ANAB $33.10
- Resistance Level
- ALX $225.06
- ANAB $37.80
- Average True Range (ATR)
- ALX 6.52
- ANAB 3.35
- MACD
- ALX -1.32
- ANAB 0.33
- Stochastic Oscillator
- ALX 25.36
- ANAB 89.34
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).